December 5, 2012
SAN ANTONIO — Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced or...
February 10, 2011
ORLANDO, Fla. — Susan Band Horwitz, Ph.D., will receive the Eighth AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted...
December 15, 2010
Stand Up To Cancer (SU2C), the charitable initiative generating public awareness of and support for ground-breaking research aimed at getting new...
December 15, 2010
PHILADELPHIA — Scientists at the Dana-Farber Cancer Institute may have uncovered a mechanism for blocking tumor angiogenesis that involves the...
December 11, 2010
SAN ANTONIO — A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use...
December 11, 2010
SAN ANTONIO — Do not delay treatment of breast cancer just because a woman is pregnant, said lead researcher Sibylle Loibl, Dr. med, of the...
December 10, 2010
SAN ANTONIO — Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women...
December 10, 2010
SAN ANTONIO — Metastatic breast cancer patients who had circulating tumor cells (CTCs) in their blood before or after high-dose chemotherapy...
December 10, 2010
SAN ANTONIO — For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared...
December 10, 2010
SAN ANTONIO — A high level of circulating tumor cells (CTCs) — cells that have detached from a tumor and are circulating in the body...
December 10, 2010
SAN ANTONIO — The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled...
December 10, 2010
SAN ANTONIO — The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer,...
December 10, 2010
SAN ANTONIO — A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among...
December 10, 2010
SAN ANTONIO — Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and...
December 9, 2010
WASHINGTON, D.C. — The American Association for Cancer Research commends the U.S. Office of the Surgeon General for its continued focus on...
December 9, 2010
SAN ANTONIO — Zoledronic acid did not improve disease free survival among women with stage II/III breast cancer according to results of the...
December 9, 2010
SAN ANTONIO — Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal...
December 9, 2010
SAN ANTONIO — Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant...
December 9, 2010
SAN ANTONIO — Only half of eligible women in the United States are getting their annual mammograms, even if they have insurance to pay for the...
December 9, 2010
SAN ANTONIO — While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact,...